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the indolent nature of T790M-positive 
TKI-resistant cells and the accelerated 
growth potential of T790M-negative 
TKI-sensitive cells.2,4
Sequist et al.5 also reported 
that two similar cases developed 
T790M at the time of TKI resistance 
and subsequently lost T790M in the 
same anatomical tumor after a TKI-
free interval. These patients both 
responded to a TKI rechallenge after 
losing the T790M.
Disappearance of T790M can be 
a predictive marker for the TKI rechal-
lenge in patients who harbored T790M 
at the previous rebiopsy. repeated 
biopsies, however, are challenging 
because of the tissue availability and 
procedural feasibility. Therefore, their 
noninvasive method to monitor T790M 
status is promising and warrants future 
studies.
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To the Editor:
I read with particular interest the 
recent article and accompanying edi-
torial on completeness of mediastinal 
lymph node dissection and survival in 
resected non–small-cell lung cancer.1,2 
As pointed out, the results come as a 
shock wave: in 62% of patients with 
pathologic N0 or N1 operated between 
1998 and 2002 in the Surveillance, 
Epidemiology, and End results data-
base, no formal mediastinal lymph 
node dissection was performed. In fact, 
none of these procedures qualifies for a 
complete r0 resection as defined by the 
International Association for the Study 
of Lung Cancer Staging Committee.
What is the current situation on 
this side of the Atlantic? In the European 
Society of Thoracic Surgeons database, 
the situation seems quite different: 
80% of patients undergo a systematic 
nodal dissection. however, it should 
be pointed out that this is a voluntary 
database from centers with a specific 
interest in thoracic surgery. Moreover, 
the large majority of data comes from 
France; so, there is clearly a shift toward 
one European country. Does this really 
reflect current practice all over Europe? 
Looking at studies specifically evaluat-
ing operative and pathological data in 
an independent way, the results are less 
encouraging, which even holds true for 
centers with a large experience in tho-
racic surgery and providing training in 
this specialty. In a recent study from the 
Netherlands, looking at four teaching 
hospitals of which one is a university 
hospital, the results are equally sur-
prising: in only 36% of the patients, 
at least three mediastinal lymph node 
stations were removed.3 Even more 
astonishing was the fact that a complete 
lymph node dissection according to the 
European Society of Thoracic Surgeons 
guidelines was performed in only 4% of 
patients. No significant difference was 
found between general surgeons with an 
additional certification in thoracic sur-
gery and cardiothoracic surgeons. This 
clearly implies that the pathological 
N classification cannot be considered 
to be accurate. Although these results 
were recorded in more recent years, 
they are very similar to those extracted 
from the Surveillance, Epidemiology, 
and End results database. Therefore, 
further teaching on this side of the 
Atlantic is certainly required.4 This was 
also concluded at a strategic meeting of 
the European Association for Cardio-
Thoracic Surgery, where completeness 
of lung cancer surgery was one of the 
discussion points.5 In this way, precise 
intraoperative staging during lung can-
cer surgery should remain a major topic 
of postgraduate courses, technocol-
leges, and teaching sessions organized 
by all major thoracic and cardiothoracic 
surgical societies.
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